Novavax Q4 Revenue Tops by $35 M, EPS Surpasses by $0.10 Yet Stock Slips
Novavax reported Q4 adjusted EPS of $0.15, beating the consensus of $0.05, and delivered $220 million in revenue versus $185 million expected. Shares slipped 2% as management offered cautious 2026 guidance for its RSV vaccine rollout.
1. Earnings Beat Consensus
Novavax reported adjusted earnings per share of $0.15 for the quarter, comfortably above the $0.05 analysts had forecast. Revenue reached $220 million, surpassing the $185 million consensus by $35 million, driven primarily by vaccine deliveries in Europe and parts of Asia.
2. Stock Reaction
Despite the stronger-than-expected results, Novavax shares fell 2% in after-hours trading. Investors appeared cautious following management’s tempered outlook on RSV vaccine uptake and potential supply constraints.
3. 2026 Guidance Outlook
Management forecast 2026 revenue of $600–650 million and reiterated plans to expand its RSV vaccine launch into additional markets. The guidance fell short of some analysts’ more optimistic projections, fueling the muted stock response.